Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 117

1.

Effects of pioglitazone and fenofibrate co-administration on bone biomechanics and histomorphometry in ovariectomized rats.

Smith SY, Samadfam R, Chouinard L, Awori M, Bénardeau A, Bauss F, Guldberg RE, Sebokova E, Wright MB.

J Bone Miner Metab. 2015 Nov;33(6):625-41. doi: 10.1007/s00774-014-0632-4. Epub 2014 Dec 23.

PMID:
25534548
2.

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.

Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, Chabenne J, Zhang L, Habegger KM, Fischer K, Campbell JE, Sandoval D, Seeley RJ, Bleicher K, Uhles S, Riboulet W, Funk J, Hertel C, Belli S, Sebokova E, Conde-Knape K, Konkar A, Drucker DJ, Gelfanov V, Pfluger PT, Müller TD, Perez-Tilve D, DiMarchi RD, Tschöp MH.

Nat Med. 2015 Jan;21(1):27-36. doi: 10.1038/nm.3761. Epub 2014 Dec 8.

PMID:
25485909
3.

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.

Finan B, Ma T, Ottaway N, Müller TD, Habegger KM, Heppner KM, Kirchner H, Holland J, Hembree J, Raver C, Lockie SH, Smiley DL, Gelfanov V, Yang B, Hofmann S, Bruemmer D, Drucker DJ, Pfluger PT, Perez-Tilve D, Gidda J, Vignati L, Zhang L, Hauptman JB, Lau M, Brecheisen M, Uhles S, Riboulet W, Hainaut E, Sebokova E, Conde-Knape K, Konkar A, DiMarchi RD, Tschöp MH.

Sci Transl Med. 2013 Oct 30;5(209):209ra151. doi: 10.1126/scitranslmed.3007218.

4.

Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat.

Bénardeau A, Verry P, Atzpodien EA, Funk JM, Meyer M, Mizrahi J, Winter M, Wright MB, Uhles S, Sebokova E.

Diabetes Obes Metab. 2013 Feb;15(2):164-74. doi: 10.1111/dom.12006. Epub 2012 Oct 3.

PMID:
22958363
5.

Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats.

Samadfam R, Awori M, Bénardeau A, Bauss F, Sebokova E, Wright M, Smith SY.

J Endocrinol. 2012 Feb;212(2):179-86. doi: 10.1530/JOE-11-0356. Epub 2011 Nov 7.

PMID:
22062085
6.

Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone.

Zhang X, Zhang R, Raab S, Zheng W, Wang J, Liu N, Zhu T, Xue L, Song Z, Mao J, Li K, Zhang H, Zhang Y, Han C, Ding Y, Wang H, Hou N, Liu Y, Shang S, Li C, Sebokova E, Cheng H, Huang PL.

Circulation. 2011 Jul 5;124(1):77-86. doi: 10.1161/CIRCULATIONAHA.110.990333. Epub 2011 Jun 20.

7.

Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.

Hansen BC, Tigno XT, Bénardeau A, Meyer M, Sebokova E, Mizrahi J.

Cardiovasc Diabetol. 2011 Jan 20;10:7. doi: 10.1186/1475-2840-10-7.

8.

Taspoglutide, a novel human once-weekly GLP-1 analogue, protects pancreatic β-cells in vitro and preserves islet structure and function in the Zucker diabetic fatty rat in vivo.

Uhles S, Wang H, Bénardeau A, Prummer M, Brecheisen M, Sewing S, Tobalina L, Bosco D, Wollheim CB, Migliorini C, Sebokova E.

Diabetes Obes Metab. 2011 Apr;13(4):326-36. doi: 10.1111/j.1463-1326.2010.01352.x.

PMID:
21205124
9.

Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat.

Sebokova E, Bénardeau A, Sprecher U, Sewing S, Tobalina L, Migliorini C.

Diabetes Obes Metab. 2010 Aug;12(8):674-82. doi: 10.1111/j.1463-1326.2010.01207.x.

PMID:
20590744
10.

Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency.

Sebokova E, Christ AD, Wang H, Sewing S, Dong JZ, Taylor J, Cawthorne MA, Culler MD.

Endocrinology. 2010 Jun;151(6):2474-82. doi: 10.1210/en.2009-1459. Epub 2010 Apr 9.

PMID:
20382695
11.

High prevalence of prediabetes and diabetes in a population exposed to high levels of an organochlorine cocktail.

Ukropec J, Radikova Z, Huckova M, Koska J, Kocan A, Sebokova E, Drobna B, Trnovec T, Susienkova K, Labudova V, Gasperikova D, Langer P, Klimes I.

Diabetologia. 2010 May;53(5):899-906. doi: 10.1007/s00125-010-1683-2. Epub 2010 Feb 25.

PMID:
20182860
12.

Aryl- and heteroaryl-substituted aminobenzo[a]quinolizines as dipeptidyl peptidase IV inhibitors.

Boehringer M, Fischer H, Hennig M, Hunziker D, Huwyler J, Kuhn B, Loeffler BM, Luebbers T, Mattei P, Narquizian R, Sebokova E, Sprecher U, Wessel HP.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):1106-8. doi: 10.1016/j.bmcl.2009.12.025. Epub 2009 Dec 6.

PMID:
20031408
13.

Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

Mattei P, Boehringer M, Di Giorgio P, Fischer H, Hennig M, Huwyler J, Koçer B, Kuhn B, Loeffler BM, Macdonald A, Narquizian R, Rauber E, Sebokova E, Sprecher U.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):1109-13. doi: 10.1016/j.bmcl.2009.12.024. Epub 2009 Dec 6.

PMID:
20031405
14.

Medium-chain fatty acids ameliorate insulin resistance caused by high-fat diets in rats.

Wein S, Wolffram S, Schrezenmeir J, Gasperiková D, Klimes I, Seböková E.

Diabetes Metab Res Rev. 2009 Feb;25(2):185-94. doi: 10.1002/dmrr.925.

PMID:
19219861
15.

Increased thyroid volume, prevalence of thyroid antibodies and impaired fasting glucose in young adults from organochlorine cocktail polluted area: outcome of transgenerational transmission?

Langer P, Kocan A, Tajtáková M, Koska J, Rádiková Z, Ksinantová L, Imrich R, Hucková M, Drobná B, Gasperíková D, Seböková E, Klimes I.

Chemosphere. 2008 Oct;73(7):1145-50. doi: 10.1016/j.chemosphere.2008.06.067. Epub 2008 Sep 14.

PMID:
18790515
16.

Possible effects of environmental nitrates and toxic organochlorines on human thyroid in highly polluted areas in Slovakia.

Rádiková Z, Tajtáková M, Kocan A, Trnovec T, Seböková E, Klimes I, Langer P.

Thyroid. 2008 Mar;18(3):353-62. doi: 10.1089/thy.2007.0182.

PMID:
18298316
17.

Reduced plaque formation induced by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion molecules.

Tikellis C, Jandeleit-Dahm KA, Sheehy K, Murphy A, Chin-Dusting J, Kling D, Sebokova E, Cooper ME, Mizrahi J, Woollard KJ.

Atherosclerosis. 2008 Jul;199(1):55-64. Epub 2008 Feb 21.

PMID:
18093596
18.

Lipoprotein lipase HindIII polymorphism influences HDL-cholesterol levels in statin-treated patients with coronary artery disease.

Javorský M, Gasperíková D, Ukropec J, Sedláková B, Riecanský I, Krizanová O, Seböková E, Dobríková M, Klimes I, Tkác I.

Wien Klin Wochenschr. 2007;119(15-16):476-82.

PMID:
17721767
19.

Possible effects of persistent organochlorinated pollutants cocktail on thyroid hormone levels and pituitary-thyroid interrelations.

Langer P, Kocan A, Tajtáková M, Rádiková Z, Petrík J, Koska J, Ksinantová L, Imrich R, Hucková M, Chovancová J, Drobná B, Jursa S, Bergman A, Athanasiadou M, Hovander L, Gasperíková D, Trnovec T, Seböková E, Klimes I.

Chemosphere. 2007 Nov;70(1):110-8. Epub 2007 Aug 10.

PMID:
17692893
20.

Thyroid ultrasound volume, structure and function after long-term high exposure of large population to polychlorinated biphenyls, pesticides and dioxin.

Langer P, Tajtáková M, Kocan A, Petrík J, Koska J, Ksinantová L, Rádiková Z, Ukropec J, Imrich R, Hucková M, Chovancová J, Drobná B, Jursa S, Vlcek M, Bergman A, Athanasiadou M, Hovander L, Shishiba Y, Trnovec T, Seböková E, Klimes I.

Chemosphere. 2007 Aug;69(1):118-27. Epub 2007 May 29.

PMID:
17537484

Supplemental Content

Loading ...
Support Center